{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:13:18Z","timestamp":1783660398544,"version":"3.55.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020521","name":"Uppsala Monitoring Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40264-026-01666-6","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:41:55Z","timestamp":1774082515000},"page":"941-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["International Medicinal Product Information Documents: A Quantitative Content Analysis of Instructions for Preventing, Mitigating, and Monitoring Adverse Drug Reactions"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-0317","authenticated-orcid":false,"given":"Daniele","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-2212","authenticated-orcid":false,"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"Jeffrey K.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-230X","authenticated-orcid":false,"given":"G. Niklas","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0811","authenticated-orcid":false,"given":"Igho J.","family":"Onakpoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"1666_CR1","unstructured":"European Commission. A guideline on Summary of Product Characteristic (SmPC). 2009 [Internet] [cited 19-05-2024]; Available from: https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/smpc_guideline_rev2_en_0.pdf"},{"key":"1666_CR2","unstructured":"US Food and Drug Administration. Electronic code of federal regulations: title 21, part 201\u2014labeling. 2024 [cited 15-08-2024]. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=201&showFR=1."},{"key":"1666_CR3","unstructured":"US Food and Drug Administration. Labeling for human prescription drug and biological products\u2014implementing the PLR content and format requirements. 2014 [cited 19-05-2024. https:\/\/www.fda.gov\/media\/71836\/download."},{"issue":"2","key":"1666_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2165\/00002018-200932020-00002","volume":"32","author":"JK Aronson","year":"2009","unstructured":"Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge: Drug Saf. 2009;32(2):91\u20138. https:\/\/doi.org\/10.2165\/00002018-200932020-00002.","journal-title":"Drug Saf"},{"issue":"11","key":"1666_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2165\/11538280-000000000-00000","volume":"33","author":"JK Aronson","year":"2010","unstructured":"Aronson JK, Ferner RE. Preventability of drug-related harms\u2014part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf. 2010;33(11):995\u20131002. https:\/\/doi.org\/10.2165\/11538280-000000000-00000.","journal-title":"Drug Saf"},{"issue":"11","key":"1666_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2165\/11538270-000000000-00000","volume":"33","author":"RE Ferner","year":"2010","unstructured":"Ferner RE, Aronson JK. Preventability of drug-related harms\u2014part I: a systematic review. Drug Saf. 2010;33(11):985\u201394. https:\/\/doi.org\/10.2165\/11538270-000000000-00000.","journal-title":"Drug Saf"},{"key":"1666_CR7","unstructured":"European Medicines Agency. Scientific guidelines with SmPC recommendations. 2024 [cited 15\/08\/2024]. https:\/\/www.ema.europa.eu\/en\/documents\/other\/scientific-guidelines-summary-product-characteristics-recommendations_en.pdf."},{"key":"1666_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/dhps.s29402","volume":"4","author":"SA Al-Aqeel","year":"2012","unstructured":"Al-Aqeel SA. Evaluation of medication package inserts in Saudi Arabia. Drug Healthc Patient Saf. 2012;4:33\u20138. https:\/\/doi.org\/10.2147\/dhps.s29402.","journal-title":"Drug Healthc Patient Saf"},{"issue":"9","key":"1666_CR9","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.3390\/ijerph120911227","volume":"12","author":"MD Bicalho","year":"2015","unstructured":"Bicalho MD, Soares DB, Botoni FA, Reis AM, Martins MA. Drug-induced nephrotoxicity and dose adjustment recommendations: agreement among four drug information sources. Int J Environ Res Public Health. 2015;12(9):11227\u201340. https:\/\/doi.org\/10.3390\/ijerph120911227.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1740774516673818","volume":"14","author":"JJ Gagne","year":"2017","unstructured":"Gagne JJ, Khan NF, Raj TS, Patel LR, Choudhry NK. Strength of evidence for labeled dosing recommendations in renal impairment. Clin Trials. 2017;14(2):219\u201321. https:\/\/doi.org\/10.1177\/1740774516673818.","journal-title":"Clin Trials"},{"issue":"11","key":"1666_CR11","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00228-013-1560-2","volume":"69","author":"TM Salgado","year":"2013","unstructured":"Salgado TM, Arguello B, Martinez-Martinez F, Benrimoj SI, Fernandez-Llimos F. Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment. Eur J Clin Pharmacol. 2013;69(11):1973\u20139. https:\/\/doi.org\/10.1007\/s00228-013-1560-2.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1666_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/0022-3859.52840","volume":"55","author":"YM Shivkar","year":"2009","unstructured":"Shivkar YM. Clinical information in drug package inserts in India. J Postgrad Med. 2009;55(2):104\u20137. https:\/\/doi.org\/10.4103\/0022-3859.52840.","journal-title":"J Postgrad Med"},{"issue":"5","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1532-5415.2005.53273.x","volume":"53","author":"KL Steinmetz","year":"2005","unstructured":"Steinmetz KL, Coley KC, Pollock BG. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc. 2005;53(5):891\u20134. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53273.x.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1666_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/bcp.12515","volume":"79","author":"B Arguello","year":"2015","unstructured":"Arguello B, Salgado TM, Fernandez-Llimos F. Assessing the information in the Summaries of Product Characteristics for the use of medicines in pregnancy and lactation. Br J Clin Pharmacol. 2015;79(3):537\u201344. https:\/\/doi.org\/10.1111\/bcp.12515.","journal-title":"Br J Clin Pharmacol"},{"issue":"5-6","key":"1666_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00228-005-0943-4","volume":"61","author":"V Bergk","year":"2005","unstructured":"Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol. 2005;61(5\u20136):327\u201335. https:\/\/doi.org\/10.1007\/s00228-005-0943-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1666_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.amjopharm.2012.01.001","volume":"10","author":"RD Boyce","year":"2012","unstructured":"Boyce RD, Handler SM, Karp JF, Hanlon JT. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: A comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother. 2012;10(2):139\u201350. https:\/\/doi.org\/10.1016\/j.amjopharm.2012.01.001.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"17","key":"1666_CR17","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2146\/ajhp110025","volume":"68","author":"CM Cheng","year":"2011","unstructured":"Cheng CM, Fu C, Guglielmo BJ, Auerbach AD. Boxed warning inconsistencies between drug information resources and the prescribing information. Am J Health Syst Pharm. 2011;68(17):1626\u201331. https:\/\/doi.org\/10.2146\/ajhp110025.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1666_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1345\/aph.1M475","volume":"44","author":"LM Wang","year":"2010","unstructured":"Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010;44(1):28\u201334. https:\/\/doi.org\/10.1345\/aph.1M475.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1666_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.7326\/m15-1097","volume":"163","author":"T Elraiyah","year":"2015","unstructured":"Elraiyah T, Gionfriddo MR, Montori VM, Murad MH. Content, consistency, and quality of black box warnings: Time for a change. Ann Intern Med. 2015;163(11):875\u20136. https:\/\/doi.org\/10.7326\/m15-1097.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1666_CR20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/cpt.1167","volume":"105","author":"S Jeong","year":"2019","unstructured":"Jeong S, Kam G, Li J, Lee S, Lee H, Noh Y, et al. Assessment of consistency of drug interaction information in drug labels among the United States, the United Kingdom, China, Japan, and Korea. Clin Pharmacol Ther. 2019;105(2):505\u201314. https:\/\/doi.org\/10.1002\/cpt.1167.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1666_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.yrtph.2014.01.013","volume":"68","author":"SH Lee","year":"2014","unstructured":"Lee SH, Shin JY, Park MJ, Park BJ. Agreement of label information of cardiovascular drugs in pregnancy among Korea, the USA, the UK, and Japan. Regul Toxicol Pharmacol. 2014;68(3):363\u20139. https:\/\/doi.org\/10.1016\/j.yrtph.2014.01.013.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"5","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/clpt.2014.156","volume":"96","author":"B Pfistermeister","year":"2014","unstructured":"Pfistermeister B, Sa\u00df A, Criegee-Rieck M, B\u00fcrkle T, Fromm MF, Maas R. Inconsistencies and misleading information in officially approved prescribing information from three major drug markets. Clin Pharmacol Ther. 2014;96(5):616\u201324. https:\/\/doi.org\/10.1038\/clpt.2014.156.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1666_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/pds.3389","volume":"22","author":"B Pfistermeister","year":"2013","unstructured":"Pfistermeister B, Schenk C, Kornhuber J, B\u00fcrkle T, Fromm MF, Maas R. Different indications, warnings and precautions, and contraindications for the same drug\u2014an international comparison of prescribing information for commonly used psychiatric drugs. Pharmacoepidemiol Drug Saf. 2013;22(3):329\u201333. https:\/\/doi.org\/10.1002\/pds.3389.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1666_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/pds.3408","volume":"22","author":"R Shimazawa","year":"2013","unstructured":"Shimazawa R, Ikeda M. Safety information in drug labeling: a comparison of the USA, the UK, and Japan. Pharmacoepidemiol Drug Saf. 2013;22(3):306\u201318. https:\/\/doi.org\/10.1002\/pds.3408.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1666_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.yrtph.2018.07.024","volume":"98","author":"D Yoon","year":"2018","unstructured":"Yoon D, Song I, Noh Y, Li J, Shin JY. Consistency of listed indications and contraindications between the U.S., the U.K., Japan, and Korea on prescription drug labels. Regul Toxicol Pharmacol. 2018;98:168\u201370. https:\/\/doi.org\/10.1016\/j.yrtph.2018.07.024.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"1666_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00228-003-0607-1","volume":"59","author":"V Reggi","year":"2003","unstructured":"Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, et al. Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol. 2003;59(4):263\u201370. https:\/\/doi.org\/10.1007\/s00228-003-0607-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2125.2005.02440.x","volume":"60","author":"RE Ferner","year":"2005","unstructured":"Ferner RE, Coleman J, Pirmohamed M, Constable SA, Rouse A. The quality of information on monitoring for haematological adverse drug reactions. Br J Clin Pharmacol. 2005;60(4):448\u201351. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02440.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1666_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036498","volume":"10","author":"MG H\u00f8jer","year":"2020","unstructured":"H\u00f8jer MG, De Bruin ML, Boskovic A, Hallgreen CE. Are monitoring instructions provided in direct healthcare professional communications (DHPCs) of sufficient quality? A retrospective analysis of DHPCs sent out between 2007 and 2018. BMJ Open. 2020;10(5):e036498. https:\/\/doi.org\/10.1136\/bmjopen-2019-036498.","journal-title":"BMJ Open"},{"issue":"1","key":"1666_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7326\/L16-0072","volume":"165","author":"CM Cheng","year":"2016","unstructured":"Cheng CM, DeLizza C. Content, consistency, and quality of black box warnings. Ann Intern Med. 2016;165(1):74. https:\/\/doi.org\/10.7326\/L16-0072.","journal-title":"Ann Intern Med"},{"key":"1666_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/9780470975053","volume-title":"Stephens' detection and evaluation of adverse drug reactions: principles and practice","author":"J Talbot","year":"2011","unstructured":"Talbot J, Aronson JK. Stephens\u2019 detection and evaluation of adverse drug reactions: principles and practice. Hoboken: Wiley; 2011."},{"issue":"4","key":"1666_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s43441-021-00265-0","volume":"55","author":"C Fukazawa","year":"2021","unstructured":"Fukazawa C, Hinomura Y, Kaneko M, Narukawa M. Factors influencing regulatory decision-making in signal management: analysis based on the signals identified from the FAERS. Ther Innov Regul Sci. 2021;55(4):685\u201395. https:\/\/doi.org\/10.1007\/s43441-021-00265-0.","journal-title":"Ther Innov Regul Sci"},{"issue":"7","key":"1666_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/pds.4446","volume":"27","author":"WN Insani","year":"2018","unstructured":"Insani WN, Pacurariu AC, Mantel-Teeuwisse AK, Gross-Martirosyan L. Characteristics of drugs safety signals that predict safety related product information update. Pharmacoepidemiol Drug Saf. 2018;27(7):789\u201396. https:\/\/doi.org\/10.1002\/pds.4446.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1666_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10. https:\/\/doi.org\/10.1186\/s12916-016-0553-2.","journal-title":"BMC Med"},{"issue":"5","key":"1666_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40264-024-01403-x","volume":"47","author":"D Sartori","year":"2024","unstructured":"Sartori D, Aronson JK, Erlanson N, Nor\u00e9n GN, Onakpoya IJ. A comparison of signals of designated medical events and non-designated medical events: results from a scoping review. Drug Saf. 2024;47(5):475\u201385. https:\/\/doi.org\/10.1007\/s40264-024-01403-x.","journal-title":"Drug Saf"},{"issue":"2","key":"1666_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-022-01258-0","volume":"46","author":"D Sartori","year":"2023","unstructured":"Sartori D, Aronson JK, Nor\u00e9n GN, Onakpoya IJ. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature. Drug Saf. 2023;46(2):109\u201320. https:\/\/doi.org\/10.1007\/s40264-022-01258-0.","journal-title":"Drug Saf"},{"issue":"5","key":"1666_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s43441-020-00130-6","volume":"54","author":"O Lagerlund","year":"2020","unstructured":"Lagerlund O, Strese S, Fladvad M, Lindquist M. WHODrug: a global, validated and updated dictionary for medicinal information. Ther Innov Regul Sci. 2020;54(5):1116\u201322. https:\/\/doi.org\/10.1007\/s43441-020-00130-6.","journal-title":"Ther Innov Regul Sci"},{"key":"1666_CR37","unstructured":"European Commission. On the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. Off J Eur Commun 1965 [cited 20-05-2024]. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:31965L0065&from=EN."},{"issue":"7","key":"1666_CR38","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamainternmed.2019.0294","volume":"179","author":"LT Perry","year":"2019","unstructured":"Perry LT, Bhasale A, Fabbri A, Lexchin J, Puil L, Joarder M, et al. Comparative analysis of medicines safety advisories released by Australia, Canada, the United States, and the United Kingdom. JAMA Intern Med. 2019;179(7):982\u20134. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0294.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1666_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5144\/0256-4947.2006.192","volume":"26","author":"N Gebran","year":"2006","unstructured":"Gebran N, Al Haidari K. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia. Ann Saudi Med. 2006;26(3):192\u20139. https:\/\/doi.org\/10.5144\/0256-4947.2006.192.","journal-title":"Ann Saudi Med"},{"issue":"2","key":"1666_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40801-020-00187-7","volume":"7","author":"A Thoenes","year":"2020","unstructured":"Thoenes A, Cariolato L, Spierings J, Pin\u00e7on A. Discrepancies between the labels of originator and generic pharmaceutical products: implications for patient safety. Drugs Real World Outcomes. 2020;7(2):131\u20139. https:\/\/doi.org\/10.1007\/s40801-020-00187-7.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"1666_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43441-022-00393-1","volume":"57","author":"I Gro\u00dfe-Michaelis","year":"2023","unstructured":"Gro\u00dfe-Michaelis I, Proestel S, Rao RM, Dillman BS, Bader-Weder S, Macdonald L, et al. MedDRA labeling groupings to improve safety communication in product labels. Ther Innov Regul Sci. 2023;57(1):1\u20136. https:\/\/doi.org\/10.1007\/s43441-022-00393-1.","journal-title":"Ther Innov Regul Sci"},{"issue":"10","key":"1666_CR42","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/bcp.14015","volume":"85","author":"RE Ferner","year":"2019","unstructured":"Ferner RE, Aronson JK. Susceptibility to adverse drug reactions. Br J Clin Pharmacol. 2019;85(10):2205\u201312. https:\/\/doi.org\/10.1111\/bcp.14015.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1666_CR43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1177\/0269881115609016","volume":"29","author":"M Nederlof","year":"2015","unstructured":"Nederlof M, Stoker LJ, Egberts TC, Heerdink ER. Instructions for clinical and biomarker monitoring in the Summary of Product Characteristics (SmPC) for psychotropic drugs: overview and applicability in clinical practice. J Psychopharmacol. 2015;29(12):1248\u201354. https:\/\/doi.org\/10.1177\/0269881115609016.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1666_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1469-8137.1912.tb05611.x","volume":"11","author":"P Jaccard","year":"1912","unstructured":"Jaccard P. The distribution of the flora in the alpine zone. New Phytol. 1912;11(2):37\u201350. https:\/\/doi.org\/10.1111\/j.1469-8137.1912.tb05611.x.","journal-title":"New Phytol"},{"key":"1666_CR45","unstructured":"R Core Team. R: a language and environment for statistical computing. 2022 [cited 01\/04\/2022]. https:\/\/www.R-project.org\/."},{"issue":"3","key":"1666_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.43","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu Z. Complex heatmap visualization. iMeta. 2022;1(3):e43. https:\/\/doi.org\/10.1002\/imt2.43.","journal-title":"iMeta"},{"issue":"18","key":"1666_CR47","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btw313.","journal-title":"Bioinformatics"},{"key":"1666_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R, Chen EM, Wallach JD, Ross JS. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. BMJ. 2022;379:e071752. https:\/\/doi.org\/10.1136\/bmj-2022-071752.","journal-title":"BMJ"},{"issue":"7559","key":"1666_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/bmj.333.7559.143","volume":"333","author":"RE Ferner","year":"2006","unstructured":"Ferner RE, Aronson JK. Communicating information about drug safety. BMJ. 2006;333(7559):143\u20135. https:\/\/doi.org\/10.1136\/bmj.333.7559.143.","journal-title":"BMJ"},{"issue":"7","key":"1666_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2165\/00002018-200629070-00002","volume":"29","author":"T Callr\u00e9us","year":"2006","unstructured":"Callr\u00e9us T. Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning. Drug Saf. 2006;29(7):557\u201366. https:\/\/doi.org\/10.2165\/00002018-200629070-00002.","journal-title":"Drug Saf"},{"issue":"7","key":"1666_CR51","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40264-025-01533-w","volume":"48","author":"MY Smith","year":"2025","unstructured":"Smith MY, Davis R, Bahri P, Saragoussi D, Nguyen V, Toyserkani GA, et al. Using mixed methods to evaluate risk minimisation programs in Europe and the USA: an innovative blueprint. Drug Saf. 2025;48(7):821\u201338. https:\/\/doi.org\/10.1007\/s40264-025-01533-w.","journal-title":"Drug Saf"},{"issue":"6","key":"1666_CR52","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjd.14530","volume":"174","author":"D Creamer","year":"2016","unstructured":"Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JKG, et al. U.K. guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194\u2013227. https:\/\/doi.org\/10.1111\/bjd.14530.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1666_CR53","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","volume":"25","author":"H Shah","year":"2024","unstructured":"Shah H, Parisi R, Mukherjee E, Phillips EJ, Dodiuk-Gad RP. Update on Stevens\u2013Johnson Syndrome and Toxic Epidermal Necrolysis: diagnosis and management. Am J Clin Dermatol. 2024;25(6):891\u2013908. https:\/\/doi.org\/10.1007\/s40257-024-00889-6.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1666_CR54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377. https:\/\/doi.org\/10.1007\/s40264-013-0131-x.","journal-title":"Drug Saf"},{"issue":"3","key":"1666_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010599","volume":"6","author":"VR Cornelius","year":"2016","unstructured":"Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents. BMJ Open. 2016;6(3):e010599. https:\/\/doi.org\/10.1136\/bmjopen-2015-010599.","journal-title":"BMJ Open"},{"issue":"12","key":"1666_CR56","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavi\u010di\u016bt\u0117 D, Carrington M, et al. HLA-A*3101 and Carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1013297.","journal-title":"N Engl J Med"},{"issue":"6982","key":"1666_CR57","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"W-H Chung","year":"2004","unstructured":"Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, et al. A marker for Stevens\u2013Johnson syndrome. Nature. 2004;428(6982):486. https:\/\/doi.org\/10.1038\/428486a.","journal-title":"Nature"},{"key":"1666_CR58","unstructured":"Anon. Arrangement between the Australian Parties and New Zealand relating to Trans-Tasman Mutual Recognition. 1996 [cited 19-05-2024]. https:\/\/www.dfat.gov.au\/sites\/default\/files\/ttmra.pdf."},{"key":"1666_CR59","unstructured":"World Health Organization. WHO Expert Committee on specifications for pharmaceutical preparations. 2021 [cited 19-05-2024]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/340323\/9789240020900-eng.pdf?sequence=1."},{"key":"1666_CR60","unstructured":"Ethiopia Food and Drug Authority. Guidelines on reliance for regulatory decision making for marketing authorization. 2023 [cited 19-05-2024]. http:\/\/www.efda.gov.et\/wp-content\/uploads\/2024\/06\/2023.12.22-Guidelines-on-Reliance-for-Regulatory-Decision-Making.pdf."},{"key":"1666_CR61","unstructured":"Ghana Food and Drug Authority. FDA reliance guideline on regulatory decision-making. 2023 [cited 19-05-2024]. https:\/\/fdaghana.gov.gh\/img\/organisation\/FDA%20RELIANCE%20GUIDELINES.pdf."},{"key":"1666_CR62","unstructured":"Medicines Control Authority of Zimbabwe. MCAZ Reliance policy. 2024 [cited 24-08-2024]. https:\/\/www.mcaz.co.zw\/wp-content\/uploads\/2024\/04\/QPM-09-Rev2_April-2024-MCAZ-Reliance-Policy.pdf."},{"key":"1666_CR63","unstructured":"Rwanda Food and Drug Authority. Guidelines on reliance for regulatory decisionmaking. 2024 [cited 19-05-2024]. https:\/\/rwandafda.gov.rw\/wp-content\/uploads\/2024\/02\/Guidelines%20on%20Reliance%20for%20Regulatory%20Decision-Making%20Rev3.pdf."},{"key":"1666_CR64","unstructured":"Saudi Food and Drug Authority. The registration rules of pharmaceutical, herbal and health product manufacturers and their products. 2022 [cited 19-05-2024]. https:\/\/www.sfda.gov.sa\/sites\/default\/files\/2023-06\/RegistrationRulesV4E_0.pdf."},{"key":"1666_CR65","unstructured":"South African Health Product Regulatory Authority. Reliance guideline. 2022 [cited 25-06-2024]. https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2022\/01\/SAHPGL-BAU-01_v4-Reliance-Guideline.pdf."},{"key":"1666_CR66","unstructured":"Pharmacy and Poisons Board. Guidelines on reliance mechanisms for marketing authorization of health products and technologies in Kenya. 2025 [cited 21-05-2025]. https:\/\/web.pharmacyboardkenya.org\/download\/guidelines-on-reliance-mechanisms-for-marketing-authorization-of-health-products-and-technologies-in-kenya\/?wpdmdl=11610&refresh=6829c5f727d471747568119&ind=1744026284472&filename=GUIDELINES-ON-RELIANCE-MECHANISMS-FOR-MARKETING-AUTHORIZATION-OF-HEALTH-PRODUCTS-AND-TECHNOLOGIES-IN-KENYA-.pdf."},{"key":"1666_CR67","unstructured":"Tanzania Medicines and Medical Devices Authority. Good Reliance practices. 2023 [cited 21-05-2025]. https:\/\/www.tmda.go.tz\/uploads\/publications\/en1678802560-GOOD%20RELIENCE%20PRACTICE%20GUIDELINE_FINAL.pdf."},{"key":"1666_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1265058","volume":"10","author":"L Danks","year":"2023","unstructured":"Danks L, Semete-Makokotlela B, Otwombe K, Parag Y, Walker S, Salek S. Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority: implications for African regulatory authorities. Front Med Lausanne. 2023;10:1265058. https:\/\/doi.org\/10.3389\/fmed.2023.1265058.","journal-title":"Front Med Lausanne"},{"issue":"5","key":"1666_CR69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40264-017-0515-4","volume":"40","author":"IJ Onakpoya","year":"2017","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: an analysis of justification. Drug Saf. 2017;40(5):431\u201341. https:\/\/doi.org\/10.1007\/s40264-017-0515-4.","journal-title":"Drug Saf"},{"issue":"D1","key":"1666_CR70","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44(D1):D1075\u20139. https:\/\/doi.org\/10.1093\/nar\/gkv1075.","journal-title":"Nucleic Acids Res"},{"issue":"125","key":"1666_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31. https:\/\/doi.org\/10.1126\/scitranslmed.3003377.","journal-title":"Sci Transl Med"},{"key":"1666_CR72","unstructured":"European Medicines Agency. Medicinal product master data for better regulation and better health 2025 [cited 30\/09\/2025]. https:\/\/www.ema.europa.eu\/en\/documents\/other\/medicinal-product-master-data-better-regulation-better-health-network-data-steering-group-ndsg-recommendations-human-product-master-data-implementation-data-management_en.pdf."},{"issue":"1","key":"1666_CR73","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.csda.2006.11.025","volume":"52","author":"C Hennig","year":"2007","unstructured":"Hennig C. Cluster-wise assessment of cluster stability. Comput Stat Data Anal. 2007;52(1):258\u201371. https:\/\/doi.org\/10.1016\/j.csda.2006.11.025.","journal-title":"Comput Stat Data Anal"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01666-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01666-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:19:38Z","timestamp":1783657178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01666-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01666-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JKA has written papers on adverse drug reactions in peer-reviewed journals and has received royalties from textbooks that he has edited or co-edited; he has often acted as an expert witness in cases involving adverse drug reactions, most often in coroners\u2019 courts. DS has communicated signals of adverse drug reactions, some of which may have also been included in product information of one or more countries. GNN is an Editorial Board member of\n                      Drug Safety\n                      ; GNN was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. MF and IJO have no relevant competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The views expressed are those of the authors and not necessarily those of the Uppsala Monitoring Centre or the University of Oxford.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The original research data are part of the electronic supplementary materials. The product information documents we retrieved are available on request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The R code is publicly available at\n                      \n                      .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DS conceptualized and designed the study with support from IJO, JKA, and GNN. MF joined the research team after registration of the protocol on MedrXiv, took part in cross-validation of scores, designed the scripts for data analysis, and provided suggestions on data presentation and analysis. DS wrote the manuscript with support from all co-authors, who also reviewed and approved drafts and the final version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"This research did not involve human participants, tissues, and\/or personal data. As such, ethics approval was not required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}